Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Research & Development: 2023-2024

Historic Research & Development for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $13.0 million.

  • Contineum Therapeutics' Research & Development rose 62.44% to $13.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $38.4 million, marking a year-over-year increase of 39.20%. This contributed to the annual value of $38.4 million for FY2024, which is 39.20% up from last year.
  • Per Contineum Therapeutics' latest filing, its Research & Development stood at $13.0 million for Q4 2024, which was up 33.79% from $9.7 million recorded in Q3 2024.
  • Contineum Therapeutics' 5-year Research & Development high stood at $13.0 million for Q4 2024, and its period low was $3.6 million during Q1 2023.
  • Over the past 2 years, Contineum Therapeutics' median Research & Development value was $8.0 million (recorded in 2023), while the average stood at $8.3 million.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Research & Development was 114.15% (2024), while the steepest drop was 16.48% (2024).
  • Quarterly analysis of 2 years shows Contineum Therapeutics' Research & Development stood at $8.0 million in 2023, then spiked by 62.44% to $13.0 million in 2024.
  • Its last three reported values are $13.0 million in Q4 2024, $9.7 million for Q3 2024, and $7.9 million during Q2 2024.